SCHEMBL2327414

SCHEMBL2327414

O=C1Cc2cccc(Br)c2C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
PIM1 P11309 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CDK5 Q00535 1/20 0.41
ROCK1 Q13464 1/20 0.41
DYRK1A Q13627 1/20 0.41
LRRK2 Q5S007 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
CYP2A6 P11509 1/20 0.40
PARP10 Q53GL7 1/20 0.39
PARP11 Q9NR21 1/20 0.39
TRPA1 O75762 1/20 0.39
IL1RN P18510 1/20 0.35
ERAP2 Q6P179 1/20 0.35
ERAP1 Q9NZ08 1/20 0.35
ABHD6 Q9BV23 2/20 0.35
HSD11B1 P28845 1/20 0.33
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29907208 1.00 CYP1A2 (0.52) CYP1A2PIM1CSNK1A1CDK5ROCK1
SCHEMBL29385577 0.83 CYP2A6 (0.52) CYP1A2PIM1CSNK1A1CDK5ROCK1
SCHEMBL1868979 0.83 CYP2A6 (0.52) CYP1A2PIM1CSNK1A1CDK5ROCK1
SCHEMBL1662187 0.83 CYP2A6 (0.52) CYP1A2PIM1CSNK1A1CDK5ROCK1
SCHEMBL14419537 0.80 MEN1 (0.40) CYP1A2PIM1CSNK1A1CDK5ROCK1
SCHEMBL7913165 0.80 CYP2A6 (0.44) CYP1A2PIM1CSNK1A1CDK5ROCK1
SCHEMBL9523617 0.78 CYP1A2 (0.52) CYP1A2CYP2A6MEN1USP2ALDH1A1
SCHEMBL17132727 0.77 TRPA1 (0.49) CYP1A2PIM1CSNK1A1CDK5ROCK1
SCHEMBL25300354 0.74 CYP1A2 (0.52) CYP1A2CYP2A6MEN1USP2ALDH1A1
SCHEMBL9672282 0.74 CYP1A2 (0.52) CYP1A2CYP2A6MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4729516-A1 SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2026-04-22 EP disclosed
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 EP disclosed
CN-119497712-A Indane derivatives as MALT1 inhibitors 希四克斯探索有限公司 2025-02-21 CN disclosed
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
US-20240398772-A1 OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) 2024-12-05 US disclosed
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHUJING BIOPHARMA CO., LTD (CN) 2024-11-07 US disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
EP-4382521-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shujing Biopharma Co., Ltd (CN) 2024-06-12 EP disclosed
EP-4375286-A1 OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shujing Biopharma Co., Ltd (CN) 2024-05-29 EP disclosed
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 EP disclosed
WO-2010042473-A1 BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS SCHERING CORPORATION (US) 2010-04-15 WO disclosed
WO-2010042473-A1 BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS SCHERING CORPORATION (US) 2010-04-15 WO disclosed
WO-2009149906-A2 PREPARATION OF SILOXY-BRIDGED METALLOCENES BASELL POLYOLEFINE GMBH (DE) 2009-12-17 WO disclosed
US-7544825-B1 Preparation of siloxy-bridged metallocenes BASELL POLYOLEFINE GMBH (DE) 2009-06-09 US disclosed
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TPH1, TPH2, GAP43 CYP1A2 1192/4885PIM1 4605/4885CSNK1A1 1572/4885
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 CYP1A2 482/4885PIM1 1464/4885CSNK1A1 2946/4885
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 CYP1A2 82/4885PIM1 4097/4885CSNK1A1 1945/4885
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 CYP1A2 482/4885PIM1 1464/4885CSNK1A1 2946/4885
US-20240398772-A1 OXASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF OGFR, OPRL1, OPRM1 CYP1A2 354/4885PIM1 4386/4885CSNK1A1 2574/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 CYP1A2 82/4885PIM1 4097/4885CSNK1A1 1945/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 CYP1A2 82/4885PIM1 4097/4885CSNK1A1 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.